Wasatch Advisors LP Decreases Stake in Certara, Inc. (NASDAQ:CERT)

Wasatch Advisors LP lowered its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,935,998 shares of the company's stock after selling 79,943 shares during the quarter. Wasatch Advisors LP owned 5.55% of Certara worth $95,168,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Venturi Wealth Management LLC increased its position in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after acquiring an additional 2,509 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. grew its holdings in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in Certara by 204.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after purchasing an additional 3,656 shares during the period. Finally, Sterling Capital Management LLC lifted its stake in Certara by 57.2% in the fourth quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock worth $77,000 after purchasing an additional 2,624 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Up 4.6 %

Shares of CERT stock traded up $0.62 on Friday, hitting $14.15. The stock had a trading volume of 2,114,112 shares, compared to its average volume of 1,188,632. Certara, Inc. has a one year low of $8.64 and a one year high of $17.94. The business has a 50 day moving average price of $11.62 and a 200 day moving average price of $11.46. The company has a market cap of $2.28 billion, a PE ratio of -70.75, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CERT. Robert W. Baird upped their target price on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. KeyCorp lifted their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday. Barclays cut their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, TD Cowen began coverage on shares of Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.